Nivolumab in Chemotherapy-Resistant Cervical Cancer: Report of a Vulvitis as a Novel Immune-Related Adverse Event and Molecular Analysis of a Persistent Complete Response
Journal for ImmunoTherapy of Cancer- United Kingdom
doi 10.1186/s40425-019-0742-6
Full Text
Abstract
Available in
Date
October 31, 2019
Authors
Publisher
BMJ